
    
      This is a Phase II, multicenter, double-masked, randomized, vehicle-controlled,
      parallel-group study designed to evaluate the efficacy and safety of KPI-121 ophthalmic
      suspension versus vehicle in subjects with signs and symptoms of inflammatory meibomian gland
      disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four
      times daily (QID).
    
  